Helio Genomics

Helio CEO, Justin Chen Li, has been selected?to join the Leadership Board of the Terasaki Institute for Biomedical Innovation (TIBI) at UCLA. The Institute operates one of the largest independent biomedical innovation infrastructures in Southern California striving to bring solutions to critical problems in human and planetary health by developing life saving products and services. Read more: https://lnkd.in/gc72URHf

We are pleased to welcome Eric Ariazi, a highly respected and experienced leader in translational cancer research including liquid biopsy assays, to Helio as our Chief Development Officer. Eric was an early employee at Freenome where he was instrumental in developing cfDNA methylation sequencing assays for cancer detection, and later at ORIC Pharmaceuticals, he implemented multiple liquid biopsy assays including cfDNA methylation sequencing to support drug development. Eric's expertise in targeted cfDNA methylation sequencing will be pivotal for Helios lab expansion endeavors as well as the further development of our diagnostics technology. https://lnkd.in/geCH8wmQ

Justin Chen Li, CEO of Helio Genomics, joins Nasdaq to discuss how the AI-driven healthcare company on a mission to save lives by developing technology that can detect cancer early from a simple blood draw. Watch more:?https://lnkd.in/eNveKa8P

Congratulations to Alex Brenner . Thank you for your outstanding financial leadership!

Congratulations to Helio's Chief Financial Officer, Alex Brenner, for being recognized as one of Washington's Top 25 CFO's. In a state that is home to more than ten Fortune 500 companies including Amazon, Starbucks and Microsoft, we are honored to have such a skilled financial leader on our team. Learn more:?https://lnkd.in/g8QjMzQd?

Helio Genomics continues to advance its diagnostics technology with HelioLiver Dx, the Company’s multi-analyte blood-based test to detect early-stage cancer in patients at high-risk for hepatocellular carcinoma. HelioLiver Dx passed pre-specified co-primary and secondary endpoints showing superiority in sensitivity and non-inferiority in specificity compared to ultrasound in Helio’s fully prospective, all-comer study. Full details can be found here:?https://lnkd.in/grH7AwNa?

Join?Helio Genomics?for a hybrid KOL event on Mon. June 17 at 10am ET featuring Mindie H. Nguyen, MD, MAS (Stanford University Medical Center), Lead Principal Investigator for the CLiMB trial, who will review results from the pivotal Clinical Trial Multi-analyte Blood Test (CLiMB) study presented at the?#EASLCongress2024. ? Register here:?https://lnkd.in/gG4MkA4g

Helio Genomics has been honored by the California Investment Forum (CIF) for its innovations in utilizing AI-based technology in developing its HelioLiver test for early liver cancer detection. Here is Helio CEO, Justin Chen Li receiving the award from?California State Controller, Malia Cohen. Learn more:?https://lnkd.in/g-Y47y3s?

This June, we are pleased to announce that Helio Chief Medical Advisor, Dr. Richard Van Etten, will present data from our Clinical Trial Multi-analyte Blood Test (CLiMB) study at the European Association for the Study of the Liver (EASL | The Home of Hepatology) Congress. CLiMB is the largest completed prospective, multi-center clinical trial for a liver cancer detection liquid biopsy test conducted in the United States. The primary goals of the study were to evaluate the sensitivity and specificity of HelioLiver compared to ultrasound for the detection of HCC within a population at high risk of HCC due to liver cirrhosis. Learn more: https://lnkd.in/g332vQ98

Helio CEO Justin Chen Li, CFA recently sat down with Precision Medicine Online reporter Catherine Shaffer and discussed recent success of the organization and dove into how Generative AI and Deep Learning can change cancer diagnostics for the better. GenomeWeb Read it here:?https://lnkd.in/gK2y526k?